Cardiac arrest
Earlier temperature control, neuroprotection, timing, safety and neurologically favourable survival.
We develop and support testable solutions for medical and societal challenges — combining research, technology and transparent evidence.
Medical innovation begins with a plausible hypothesis and becomes valuable through well-designed studies. We show what mechanism data, preclinical findings and external clinical signals already support, then define the next measurable validation step.
Our current planning covers several time-critical indications. The effect scenarios are transparent sensitivity analyses, not claims of AIRCHILL efficacy.
Earlier temperature control, neuroprotection, timing, safety and neurologically favourable survival.
Neuroprotection around thrombectomy and the question whether an additional early intervention can improve functional outcome.
Established therapeutic hypothermia provides a strong biological precedent; any new transport or early-cooling approach requires separate paediatric validation.
Population selection, intracranial pressure, timing, duration, rewarming and clinically relevant outcomes.
Cooling speed is critical. A future respiratory approach would need to be evaluated as a complementary option, not as a replacement for established rapid cooling.
A separate research field with external head/neck cooling signals; typical concussion is not a current respiratory AIRCHILL use case.
Public patent records list EP3509683B1 and US11395900B2 and identify Fabian Temme as holder/assignee. The public register view is presented transparently and does not replace formal chain-of-title due diligence.
Key projects include Medicalcooling/AIRCHILL, InjuryDetector, GritArmor and open-source software published by Ethical Saving.
Research and development around early cooling and neuroprotection.
District-level German ambulance and emergency physician fee structures, payer logic and primary sources.
Selected software and AI-assisted website infrastructure are published openly.
Our current proposal would open the existing German evidence-generation pathway under §137e SGB V to emergency medical services and add a temporary, transport-independent trial reimbursement route under §133 SGB V.
Book a privacy-conscious 30-minute meeting with Fabian Temme.
Donations support nonprofit research, study preparation, evidence development and project work. They do not guarantee a medical outcome.
These figures mirror the current German source page. They are sensitivity analyses for study planning and must not be read as demonstrated AIRCHILL effects.
An operative assumption of 7,500 potentially reachable suitable patients per year gives 75, 225 or 375 additional favourable neurological outcomes at hypothetical absolute gains of +1, +3 or +5 percentage points. Registry data and PRINCESS/HYPERION provide context, not an AIRCHILL effect size.
Using 21,609 mechanical thrombectomies in Germany in 2024 as the current model anchor, the same +1/+3/+5-point scenarios correspond mathematically to about 216, 648 or 1,080 additional patients with mRS 0–2. The COTTIS signal is non-randomized; COTTIS-2 is needed for stronger inference.
Against a derived system frame of about 981 cases, +1/+3/+5 points would equal roughly 10, 29 or 49 favourable outcomes. Established neonatal hypothermia does not prove added benefit from a new device; a separate paediatric safety, dosing and regulatory programme would be required.
Per 100 comparable severe cases, the same scenarios equal 1, 3 or 5 additional survivors. Heat-attributable population deaths are not a diagnosed heatstroke cohort and are not an AIRCHILL target population. Established rapid active cooling remains the reference treatment.
With 7,500 potentially reachable severe cases used only as an operational assumption, +1/+3/+5 points equal 75, 225 or 375 favourable outcomes. AIRCHILL has treated 0 TBI patients; feasibility and subsequent outcome studies would be required.
This remains a separate research field. Typical concussion patients are awake and do not require invasive ventilation, so it is not a current respiratory AIRCHILL use case. Future modelling should prefer days to return-to-activity or validated symptom scales over percentage-point scenarios.